Current Problems in Cardiology
Volume 35, Issue 4 , Pages 176-220 , April 2010

Cardiovascular Magnetic Resonance Imaging of Myocardial Infarction, Viability, and Cardiomyopathies

  • Amy M. West, MD
    • ,
  • Christopher M. Kramer, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Christopher M. Kramer, MD, University of Virginia Health System, Departments of Medicine and Radiology, Lee St, Box 800170, Charlottesville, VA 22908

References 

  1. Wu K. CMR as the “one-stop shop” for risk stratification after infarction?. JACC Cardiovasc Imaging. 2009;2:843–845
  2. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American Heart Association. Circulation. 2002;105:539–542
  3. Holman ER, Buller VG, de Roos A, et al. Detection and quantification of dysfunctional myocardium by magnetic resonance imaging (A new three-dimensional method for quantitative wall-thickening analysis). Circulation. 1997;95:924–931
  4. Gotte MJ, van Rossum AC, Twisk JW, et al. Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. J Am Coll Cardiol. 2001;37:808–817
  5. Bottini PB, Carr AA, Prisant LM, et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens. 1995;8:221–228
  6. Ichikawa Y, Sakuma H, Kitagawa K, et al. Evaluation of left ventricular volumes and ejection fraction using fast steady-state cine MR imaging: comparison with left ventricular angiography. J Cardiovasc Magn Reson. 2003;5:333–342
  7. Persson E, Carlsson M, Palmer J, et al. Evaluation of left ventricular volumes and ejection fraction by automated gated myocardial SPECT versus cardiovascular magnetic resonance. Clin Physiol Funct Imaging. 2005;25:135–141
  8. Bellenger NG, Davies LC, Francis JM, et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000;2:271–278
  9. Nowosielski M, Schocke M, Mayr A, et al. Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. J Cardiovasc Magn Reson. 2009;11:22
  10. Bodi V, Sanchis J, Nunez J, et al. Prognostic value of a comprehensive cardiac magnetic resonance assessment soon after a first ST-segment elevation myocardial infarction. JACC Cardiovasc Imaging. 2009;2:835–842
  11. Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischemic cardiomyopathies. Eur Heart J. 2005;26:1461–1474
  12. Wesbey GE, Higgins CB, McNamara MT, et al. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology. 1984;153:165–169
  13. Judd RM, Lugo-Olivieri CH, Arai M, et al. Physiologic basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation. 1995;92:1902–1910
  14. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile dysfunction. Circulation. 1999;100:1992–2002
  15. Fieno DS, Kim RJ, Chen EL, et al. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol. 2000;36:1985–1991
  16. de Roos A, van Rossum AC, van der Wall E, et al. Reperfused and non-reperfused myocardial infarction: diagnostic potential of Gd-DTPA enhanced MR imaging. Radiology. 1989;172:717–720
  17. Lima JA, Judd RM, Bazille A, et al. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Circulation. 1995;92:1117–1125
  18. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215–223
  19. Hundley GW, Narula J. Cardiovascular magnetic resonance imaging: is only one shop worth the stop?. JACC Cardiovasc Imaging. 2009;2:1144–1145
  20. Thomson LE, Kim RJ, Judd RM. Magnetic resonance imaging for the assessment of myocardial viability. J Magn Reson Imaging. 2004;19:771–788
  21. Kellman P, Arai AE, McVeigh ER, et al. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med. 2002;47:372–383
  22. Sievers B, Elliott MD, Hurwitz LM, et al. Rapid detection of myocardial infarction by subsecond, free-breathing delayed contrast-enhancement cardiovascular magnetic resonance. Circulation. 2007;115:236–244
  23. Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson. 2005;7:481–485
  24. Kramer CM, Barkhausen J, Flamm SD, et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008;10:35
  25. Hundley WG, Bluemke D, Bogaert JG, et al. Society for cardiovascular magnetic resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson. 2009;11:5
  26. Choi KM, Kim RJ, Gubernikoff G, et al. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation. 2001;104:1101–1107
  27. Ortiz-Perez JT, Rodriguez J, Meyers SN, et al. Correspondence between the 17-segment model and coronary arterial imaging using contrast-enhanced cardiac magnetic resonance imaging. JACC Cardiovasc Imaging. 2008;1:282–293
  28. Kim RJ, Albert TS, Wible JH, et al. Performance of delayed-enhancement myocardial resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction. Circulation. 2008;117:629–637
  29. Wagner A, Mahrholdt H, Thomson L, et al. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol. 2006;47:2027–2033
  30. Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374–379
  31. Ibrahim T, Bulow HP, Hackl T, et al. Diagnostic value of contrast-enhanced magnetic resonance imaging and single-photon emission computed tomography for detection of myocardial necrosis early after acute myocardial infarction. J Am Coll Cardiol. 2007;49:208–216
  32. Reimer KA, Jennings RB. The changing anatomic reference base of evolving myocardial infarction (Underestimation of myocardial collateral blood flow and overestimation of experimental anatomic infarct size due to tissue edema, hemorrhage and acute inflammation). Circulation. 1979;60:866–876
  33. Fieno DS, Hillenbrand HB, Rehwald WG, et al. Infarct resorption, compensatory hypertrophy and differing patterns of ventricular remodeling following acute myocardial infarction of varying size. J Am Coll Cardiol. 2004;43:2124–2131
  34. Ingkanisorn WP, Rhoads KL, Aletras AH, et al. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol. 2004;43:2253–2259
  35. Choi CJ, Haji-Momenian S, DiMaria JM, et al. Infarct involution and improved function during healing of acute myocardial infarction: the role of microvascular obstruction. J Cardiovasc Magn Reson. 2004;6:917–925
  36. Lund GK, Stork A, Muellerleile K, et al. Remodeling and analysis of infarct resorption in patients with reperfused myocardial infarcts by using contrast enhanced MR imaging. Radiology. 2007;245:95–102
  37. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94:730–736
  38. Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol. 2005;46:1229–1235
  39. Kim HW, Klem I, Shah DJ, et al. Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. PLoS Med. 2009;6:e1000057
  40. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113:2733–2743
  41. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008;118:1011–1020
  42. Steel K, Broderick R, Gandla V, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation. 2009;120:1390–1400
  43. Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007;115:2006–2014
  44. Deneke T, Muller KM, Lemke B, et al. Human histopathology of electroanatomic mapping after cooled-tip radiofrequency ablation to treat ventricular tachycardia in remote myocardial infarction. J Cardiovasc Electrophysiol. 2005;16:1246–1251
  45. Yan AT, Shayne AJ, Brown KA, et al. Contrast-enhanced cardiovascular magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32–39
  46. Roes SD, Borleffs CJ, van der Geest RJ, et al. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardiac defibrillator. Circ Cardiovasc Imaging. 2009;2:183–190
  47. Kribben A, Witzke O, Hillen U, et al. Nephrogenic systemic fibrosis: pathogenesis, diagnosis and therapy. J Am Coll Cardiol. 2009;53:1621–1628
  48. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281–292
  49. Reffelmann T, Kloner RA. The “no-reflow” phenomenon: basic science and clinical correlates. Heart. 2002;20:39–45
  50. Rogers WJ, Kramer CM, Geskin G, et al. Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction. Circulation. 1999;99:744–750
  51. Nijveldt R, Beek AM, Hirsch A, et al. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol. 2008;52:181–189
  52. Yan AT, Gibson CM, Larose E, et al. Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first pass perfusion and late gadolinium enhancement imaging. J Cardiovasc Magn Reson. 2006;8:831–837
  53. Wu KC, Kim RJ, Bleumke DA, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol. 1998;32:1756–1764
  54. Kwong RY, Schussheim AE, Rekhraj S, et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation. 2003;107:531–537
  55. Rogers WJ, Kramer CM, Geskin G, et al. Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction. Circulation. 1999;99:744–750
  56. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765–772
  57. Hombach V, Grebe OC, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005;26:549–557
  58. Kramer CM. The prognostic significance of microvascular obstruction after myocardial infarction as defined by cardiac magnetic resonance. Eur Heart J. 2005;26:532–533
  59. Choi CJ, Haji-Momenian S, DiMaria JM, et al. Infarct involution and improved function during healing of acute myocardial infarction: the role of microvascular obstruction. J Cardiovasc Magn Reson. 2004;6:917–925
  60. Wisenberg G, Prato FS, Carroll SE, et al. Serial nuclear magnetic resonance imaging of acute myocardial infarction with and without reperfusion. Am Heart J. 1998;115:510–518
  61. Klocke FJ. Emerging applications of T2-weighted cardiac magnetic resonance imaging in acute ischemic syndromes. J Am Coll Cardiol. 2009;14:1202–1203
  62. Aletras AH, Tilak GS, Natanzon A, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113:1865–1870
  63. Abdel-Aty H, Zagrosek A, Schulz-Menger J, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation. 2004;109:2411–2416
  64. Friedrich MG, Abdel-Aty H, Taylor A, et al. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1581–1587
  65. Carlsson M, Ubachs JF, Hedstrom E, et al. Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging. 2009;2:569–576
  66. Mikami Y, Sakuma H, Nagata M, et al. Relation between signal intensity on T2-weighted MR images and presence of microvascular obstruction in patients with acute myocardial infarction. Am J Roentgenol. 2009;193:W321–W326
  67. Cury RC, Shash K, Nagurney JT, et al. Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. Circulation. 2008;118:837–844
  68. Kellman P, Aletras AH, Mancini C, et al. 2-prepared SSFP improves diagnostic confidence in edema imaging in acute myocardial infarction compared to turbo spin echo. Magn Reson Med. 2007;57:891–897
  69. Patel AR, Epstein FH, Kramer CK. Evaluation of the microcirculation. J Nucl Cardiol. 2008;15:698–708
  70. Barkhausen J, Hunold P, Jochims M, et al. Imaging of myocardial perfusion with magnetic resonance. J Magn Reson Imaging. 2004;19:750–757
  71. Gerber BL, Raman SV, Nayak K, et al. Myocardial first-pass perfusion cardiovascular magnetic resonance: history, theory and current state of the art. J Cardiovasc Magn Reson. 2008;10:18
  72. Schwitter J, Wacker CM, van Rossum AC, et al. MR-Impact: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicenter, multivendor, randomized trial. Eur Heart J. 2008;29:480–489
  73. Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease. J Am Coll Cardiol. 2007;50:1343–1353
  74. Klem I, Heitner JF, Shah DJ, et al. Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol. 2006;47:1630–1638
  75. Plein S, Greenwood JP, Ridgway JP, et al. Assessment of non-ST elevation acute coronary syndrome with cardiac magnetic resonance imaging. J Am Coll Cardiol. 2004;44:2173–2181
  76. Gutberlet M, Noeske R, Schwinge K, et al. Comprehensive cardiac magnetic resonance imaging at 3.0 Tesla: feasibility and implications for clinical applications. Invest Radiol. 2006;41:154–167
  77. Cheng AS, Pegg TJ, Karamitsos TD, et al. Cardiovascular magnetic resonance perfusion imaging at 3-Tesla for the detection of coronary artery disease. J Am Coll Cardiol. 2007;49:2440–2449
  78. Mollet NR, Dymarkowski S, Volders W, et al. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation. 2002;106:2873–2876
  79. Srichai MB, Junor C, Rodriguez LL, et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J. 2006;152:75–84
  80. Weinsaft JW, Kim HW, Shah DJ, et al. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance: prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol. 2008;52:148–157
  81. Assomull RG, Lyne JC, Keenan N, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin and unobstructed coronary arteries. Eur Heart J. 2007;28:1242–1249
  82. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary artery bypass surgery for chronic stable angina. Circulation. 1985;72:123–135
  83. Shan K, Constantine G, Sivananthan M, et al. Role of cardiac magnetic resonance imaging in the assessment of myocardial viability. Circulation. 2004;109:1328–1334
  84. Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–1158
  85. Baer FM, Voth E, Schneider CA, et al. Comparison of low dose dobutamine gradient echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease (A functional and morphological approach to the detection of residual myocardial viability). Circulation. 1995;91:1006–1015
  86. Baer FM, Voth E, LaRosee K, et al. Comparison of dobutamine transesophageal echocardiography and dobutamine magnetic resonance imaging for detection of residual myocardial viability. Am J Cardiol. 1996;78:415–419
  87. Nowosielski M, Schocke M, Mayr A, et al. Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. J Cardiovasc Magn Reson. 2009;11:22
  88. Schinkel AF, Bax JJ, Poldermans D, et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375–410
  89. Baer FM, Theissen P, Schneider CA, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol. 1998;31:1040–1048
  90. Geskin G, Kramer CK, Rogers WJ, et al. Quantitative assessment of myocardial viability after infarction by dobutamine magnetic resonance tagging. Circulation. 1998;98:217–223
  91. Reichek N. MRI myocardial tagging. J Magn Reson Imaging. 1999;10:609–616
  92. Kuhl HP, Beek AM, van der Weerdt AP, et al. Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2003;41:1341–1348
  93. Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation. 2002;105:162–167
  94. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–1453
  95. Bove CM, DiMaria JM, Voros S, et al. Dobutamine response and myocardial infarct transmurality: functional improvement after coronary artery bypass grafting—initial experience. Radiology. 2006;240:835–841
  96. Wellnhofer E, Olariu A, Klein C, et al. Magnetic resonance low-dose dobutamine test is superior to scar quantification for prediction of functional recovery. Circulation. 2004;109:2172–2174
  97. Samady H, Choi CJ, Ragosta M, et al. Electromechanical mapping identifies improvement in function and retention of contractile reserve after revascularization in ischemic cardiomyopathy. Circulation. 2004;110:2410–2416
  98. Karamitos TD, Francis JM, Myerson S, et al. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407–1424
  99. Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in non-ischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–2421
  100. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54–59
  101. Casolo G, Minneci S, Manta R, et al. Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement. Am Heart J. 2006;151:101–108
  102. Soriano CJ, Ridocci F, Estornell J, et al. Noninvasive diagnosis of coronary artery disease in patients with heart failure and systolic dysfunction of uncertain etiology, using late gadolinium-enhanced cardiovascular magnetic resonance. J Am Coll Cardiol. 2005;45:743–748
  103. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–1985
  104. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53:1475–1487
  105. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–1320
  106. Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112:855–861
  107. Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying cardiovascular magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53:284–291
  108. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260–2264
  109. Adabag SA, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369–1374
  110. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J. 1994;71:215–218
  111. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multi-center study. J Am Coll Cardiol. 1997;30:1512–1520
  112. Tandri H, Bomma C, Calkins H, et al. Magnetic resonance and computed tomography imaging of arrhythmogenic right ventricular dysplasia. J Magn Reson Imaging. 2004;19:848–858
  113. Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50:2101–2110
  114. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51:1022–1030
  115. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–193
  116. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683–1690
  117. Vignaux O, Dhote R, Duboc D, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002;26:762–767
  118. Kramer CM, Narula J. Atherosclerotic plaque imaging: the last frontier for cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009;2:916–918
  119. Kawasaki T, Koga S, Koga N, et al. Characterization of hyperintense plaque with non-contrast T1-weighted cardiac magnetic resonance coronary plaque imaging: comparison with multi-slice computed tomography and intravascular ultrasound. JACC Cardiovasc Imaging. 2009;2:720–728

 Dr. Christopher M. Kramer, is a Consultant and has Research support for Siemens Medical Solutions (Erlangen, Germany), Research grant: Astellas (Deerfield, IL).

PII: S0146-2806(09)00158-3

doi: 10.1016/j.cpcardiol.2009.12.002

Current Problems in Cardiology
Volume 35, Issue 4 , Pages 176-220 , April 2010

Article Tools

* Image Usage & Resolution